GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021

Stock Information for GT Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About GT Biopharma Inc.

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split
Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote "FOR" All Proposed Items at the Upcoming Special Meeting of Stockholders
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia
GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
GT Biopharma Reports Third Quarter 2023 Financial Results
GT Biopharma Reports Second Quarter 2023 Financial Results
GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.